WO2001036685A3 - Differential gene expression in cancer - Google Patents

Differential gene expression in cancer Download PDF

Info

Publication number
WO2001036685A3
WO2001036685A3 PCT/US2000/031809 US0031809W WO0136685A3 WO 2001036685 A3 WO2001036685 A3 WO 2001036685A3 US 0031809 W US0031809 W US 0031809W WO 0136685 A3 WO0136685 A3 WO 0136685A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
gene expression
differential gene
methods
glioblastoma
Prior art date
Application number
PCT/US2000/031809
Other languages
French (fr)
Other versions
WO2001036685A2 (en
Inventor
Roger A Kroes
Joseph R Moskal
Hirotaka Yamamoto
Original Assignee
Nyxis Neurotherapies Inc
Roger A Kroes
Joseph R Moskal
Hirotaka Yamamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyxis Neurotherapies Inc, Roger A Kroes, Joseph R Moskal, Hirotaka Yamamoto filed Critical Nyxis Neurotherapies Inc
Priority to AU19223/01A priority Critical patent/AU1922301A/en
Publication of WO2001036685A2 publication Critical patent/WO2001036685A2/en
Publication of WO2001036685A3 publication Critical patent/WO2001036685A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

The invention is directed towards methods for ascertaining gene expression characteristic for cancer, in particular brain cancers such as glioblastoma, and the sequences identified thereby. Compositions, methods and kits encompassing such are provided herein.
PCT/US2000/031809 1999-11-17 2000-11-17 Differential gene expression in cancer WO2001036685A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19223/01A AU1922301A (en) 1999-11-17 2000-11-17 Differential gene expression in cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16610699P 1999-11-17 1999-11-17
US16605699P 1999-11-17 1999-11-17
US60/166,056 1999-11-17
US60/166,106 1999-11-17

Publications (2)

Publication Number Publication Date
WO2001036685A2 WO2001036685A2 (en) 2001-05-25
WO2001036685A3 true WO2001036685A3 (en) 2002-01-10

Family

ID=26861932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031809 WO2001036685A2 (en) 1999-11-17 2000-11-17 Differential gene expression in cancer

Country Status (2)

Country Link
AU (1) AU1922301A (en)
WO (1) WO2001036685A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002012332A2 (en) * 2000-08-07 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
MXPA05012613A (en) 2003-05-23 2006-05-25 Genentech Inc Compositions and methods for the diagnosis and treatment of tumors of glial origin.
US20070141066A1 (en) * 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
BRPI0918868B8 (en) 2008-09-18 2021-05-25 Naurex Inc nmda receptor modulating compounds and compositions comprising the same
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (en) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
US8747530B2 (en) 2011-02-15 2014-06-10 Lta Corporation Systems for water extraction from air
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
HRP20221545T1 (en) 2013-01-29 2023-03-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009772A (en) 2013-01-29 2016-05-31 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof.
MX2015009773A (en) 2013-01-29 2016-08-05 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof.
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3458458B1 (en) 2016-05-19 2020-11-04 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109937204B (en) 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 Spiro-lactam NMDA receptor modulators and uses thereof
US11370790B2 (en) 2016-08-01 2022-06-28 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
CA3031562A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
EA201990428A1 (en) 2016-08-01 2019-08-30 Аптиникс Инк. SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EP3746447A1 (en) 2018-01-31 2020-12-09 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053319A2 (en) * 1997-05-21 1998-11-26 The Johns Hopkins University Gene expression profiles in normal and cancer cells
US5858712A (en) * 1997-02-06 1999-01-12 Incyte Pharmaceuticals, Inc. CDNA encoding a LEA-motif developmental protein homologous to avian px19
WO1999022243A1 (en) * 1997-10-24 1999-05-06 Human Genome Sciences, Inc. 148 human secreted proteins
WO1999023252A1 (en) * 1997-11-05 1999-05-14 Isis Innovation Limited Cancer gene
WO1999024469A1 (en) * 1997-11-07 1999-05-20 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999053062A2 (en) * 1998-04-16 1999-10-21 Cedars-Sinai Health System, Et Al Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof
WO2000028090A2 (en) * 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858712A (en) * 1997-02-06 1999-01-12 Incyte Pharmaceuticals, Inc. CDNA encoding a LEA-motif developmental protein homologous to avian px19
WO1998053319A2 (en) * 1997-05-21 1998-11-26 The Johns Hopkins University Gene expression profiles in normal and cancer cells
WO1999022243A1 (en) * 1997-10-24 1999-05-06 Human Genome Sciences, Inc. 148 human secreted proteins
WO1999023252A1 (en) * 1997-11-05 1999-05-14 Isis Innovation Limited Cancer gene
WO1999024469A1 (en) * 1997-11-07 1999-05-20 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999053062A2 (en) * 1998-04-16 1999-10-21 Cedars-Sinai Health System, Et Al Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof
WO2000028090A2 (en) * 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] EMBL; 12 April 1997 (1997-04-12), STRAUSBERG R. ET AL: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor gene index", XP002181163, Database accession no. EM_EST:HS1191117 *
DATABASE EBI [online] EMBL; 27 April 1997 (1997-04-27), ADAMS M.D. ET AL: "Use of a random BAC End Sequence Database for Sequence-Ready Map Building", XP002181161, Database accession no. EM_GSS:AQ005923 *
DATABASE EBI [online] EMBL; 27 July 1999 (1999-07-27), AGOSTINO M.J. ET AL: "SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM", XP002181162, Database accession no. GSN:AAX60579 *
DATABASE EBI [online] EMBL; 5 January 1998 (1998-01-05), HILLIER ET AL: "WashU-NCI human EST Project", XP002174758, Database accession no. EM_EST:AA705392 *
LAL ANITA ET AL: "A public database for gene expression in human cancers.", CANCER RESEARCH, vol. 59, no. 21, 1 November 1999 (1999-11-01), pages 5403 - 5407, XP002174720, ISSN: 0008-5472 *
YAMAGUCHI FUMIO ET AL: "Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 2, 1994, 1994, pages 484 - 488, XP002141422, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU1922301A (en) 2001-05-30
WO2001036685A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO2001036685A3 (en) Differential gene expression in cancer
WO2000028090A3 (en) Diagnostic assay for cancer
WO2005017207A3 (en) Methods and compositions for detecting colon cancers
WO2003031932A3 (en) Methods and compositions for detecting colon cancers
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2003012067A3 (en) Expression profile of prostate cancer
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
WO2005027962A3 (en) 4’-thionucleosides and oligomeric compounds
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2006020947A9 (en) Phosphonate fluorescent dyes and conjugates
WO2004037988A3 (en) Methods for synthesizing complementary dna
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2006010150A3 (en) Housekeeping genes and methods for identifying the same
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
WO2001052904A3 (en) Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2004058153A9 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2000066528A3 (en) Quinones for treatment of diseases
EP1007553A4 (en) Zonula occludens toxin receptors
WO2004031402A3 (en) Methylation profile of cancer
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2003035889A3 (en) Compositions and methods for bacteria detection
AU2002245225A1 (en) Repeat-free probes for molecular cytogenetics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase